# A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

> **NCT03861052** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 636 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT03861052
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-31
- **Target enrollment:** 636 (ACTUAL)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03861052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03861052, "A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03861052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*